201 related articles for article (PubMed ID: 35348643)
1. Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort.
Zanatta E; Huscher D; Ortolan A; Avouac J; Airò P; Balbir-Gurman A; Siegert E; Matucci Cerinic M; Cozzi F; Riemekasten G; Hoffmann-Vold AM; Distler O; Gabrielli A; Heitmann S; Hunzelmann N; Montecucco C; Morovic-Vergles J; Ribi C; Doria A; Allanore Y;
Rheumatology (Oxford); 2022 Nov; 61(12):4786-4796. PubMed ID: 35348643
[TBL] [Abstract][Full Text] [Related]
2. Interstitial lung disease in systemic sclerosis: data from the spanish scleroderma study group.
Sánchez-Cano D; Ortego-Centeno N; Callejas JL; Fonollosa Plá V; Ríos-Fernández R; Tolosa-Vilella C; Espinosa-Garriga G; Colunga-Argüelles D; Egurbide-Arberas MV; Rubio-Rivas M; Freire M; Ríos-Blanco JJ; Trapiella-Martínez L; Rodríguez-Carballeira M; Marín-Ballvé A; Pla-Salas X; Simeón-Aznar CP
Rheumatol Int; 2018 Mar; 38(3):363-374. PubMed ID: 29322341
[TBL] [Abstract][Full Text] [Related]
3. Clinical phenotype in scleroderma patients based on autoantibodies.
Santos CS; Morales CM; Castro CÁ; Álvarez ED
Rheumatol Adv Pract; 2023 Apr; 7(Suppl 1):i26-i33. PubMed ID: 36968636
[TBL] [Abstract][Full Text] [Related]
4. Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status.
Simeón-Aznar CP; Fonollosa-Plá V; Tolosa-Vilella C; Espinosa-Garriga G; Ramos-Casals M; Campillo-Grau M; García-Hernández FJ; Castillo-Palma MJ; Sánchez-Román J; Callejas-Rubio JL; Ortego-Centeno N; Egurbide-Arberas MV; Trapiellla-Martínez L; Gallego-Villalobos M; Sáez-Comet L; Velilla-Marco J; Camps-García MT; de Ramón-Garrido E; Esteban Marcos EM; Pallarés-Ferreres L; Hidalgo-Tenorio C; Sabio-Sánchez JM; Gómez-de la Torre R; Salvador-Cervello G; Rios-Blanco JJ; Gil-Aguado A; Vilardell-Tarrés M
Semin Arthritis Rheum; 2012 Jun; 41(6):789-800. PubMed ID: 22169458
[TBL] [Abstract][Full Text] [Related]
5. Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study.
Kranenburg P; van den Hombergh WM; Knaapen-Hans HK; van den Hoogen FH; Fransen J; Vonk MC
Rheumatology (Oxford); 2016 Nov; 55(11):2001-2008. PubMed ID: 27520796
[TBL] [Abstract][Full Text] [Related]
6. Thinking outside the box--The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect.
Srivastava N; Hudson M; Tatibouet S; Wang M; Baron M; Fritzler MJ;
Semin Arthritis Rheum; 2015 Oct; 45(2):184-9. PubMed ID: 25959492
[TBL] [Abstract][Full Text] [Related]
7. Serodiscordant patients with systemic sclerosis: when antibody does not correspond to skin involvement.
Iniesta Arandia N; Espinosa G; Tolosa Vilella C; Guillén Del Castillo A; Rubio Rivas M; Freire M; Vargas Hitos JA; Todolí Parra JA; Rodríguez Carballeira M; Marín Ballvé A; Colunga Argüelles D; González de Echávarri Pérez de Heredia C; Ortego-Centeno N; Trapiella Martínez L; Pla Salas X; Chamorro AJ; Perales Fraile I; Ruiz Muñoz M; Fernández de la Puebla Giménez RÁ; Madroñero Vuelta AB; Pons Martín Del Campo I; Jiménez Pérez de Heredia I; González García A; Fonollosa Pla V; Simeón Aznar CP;
Clin Exp Rheumatol; 2020; 38 Suppl 125(3):106-114. PubMed ID: 31969223
[TBL] [Abstract][Full Text] [Related]
8. Clinical differences between Thai systemic sclerosis patients with positive versus negative anti-topoisomerase I.
Foocharoen C; Suwannachat P; Netwijitpan S; Mahakkanukrauh A; Suwannaroj S; Nanagara R;
Int J Rheum Dis; 2016 Mar; 19(3):312-20. PubMed ID: 25293362
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database.
Lescoat A; Huang S; Carreira PE; Siegert E; de Vries-Bouwstra J; Distler JHW; Smith V; Del Galdo F; Anic B; Damjanov N; Rednic S; Ribi C; Bancel DF; Hoffmann-Vold AM; Gabrielli A; Distler O; Khanna D; Allanore Y;
JAMA Dermatol; 2023 Aug; 159(8):837-847. PubMed ID: 37378994
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database.
Frantz C; Huscher D; Avouac J; Hachulla E; Balbir-Gurman A; Riemekasten G; Siegert E; Lazzaroni MG; Carreira PE; Vettori S; Zanatta E; Ullman S; Czirjàk L; Kowal-Bielecka O; Distler O; Matucci-Cerinic M; Allanore Y;
Autoimmun Rev; 2020 Feb; 19(2):102452. PubMed ID: 31838157
[TBL] [Abstract][Full Text] [Related]
11. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.
Kuwana M; Allanore Y; Denton CP; Distler JHW; Steen V; Khanna D; Matucci-Cerinic M; Mayes MD; Volkmann ER; Miede C; Gahlemann M; Quaresma M; Alves M; Distler O
Arthritis Rheumatol; 2022 Mar; 74(3):518-526. PubMed ID: 34514739
[TBL] [Abstract][Full Text] [Related]
12. Sex-specific risk of anti-topoisomerase antibodies on mortality and disease severity in systemic sclerosis: 10-year analysis of the Leiden CCISS and EUSTAR cohorts.
Liem SIE; Boonstra M; le Cessie S; Riccardi A; Airo P; Distler O; Matucci-Cerinic M; Caimmi C; Siegert E; Allanore Y; Huizinga TWJ; Toes REM; Scherer HU; de Vries-Bouwstra JK;
Lancet Rheumatol; 2022 Oct; 4(10):e699-e709. PubMed ID: 38265968
[TBL] [Abstract][Full Text] [Related]
13. Systemic sclerosis sine scleroderma: a multicenter study of 1417 subjects.
Diab S; Dostrovsky N; Hudson M; Tatibouet S; Fritzler MJ; Baron M; Khalidi N;
J Rheumatol; 2014 Nov; 41(11):2179-85. PubMed ID: 25274885
[TBL] [Abstract][Full Text] [Related]
14. Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: Inception cohort study.
Wangkaew S; Euathrongchit J; Wattanawittawas P; Kasitanon N; Louthrenoo W
Mod Rheumatol; 2016 Jul; 26(4):588-93. PubMed ID: 26561397
[TBL] [Abstract][Full Text] [Related]
15. Different clinical features in patients with limited and diffuse cutaneous systemic sclerosis.
Ostojić P; Damjanov N
Clin Rheumatol; 2006 Jul; 25(4):453-7. PubMed ID: 16261285
[TBL] [Abstract][Full Text] [Related]
16. Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis.
Moinzadeh P; Aberer E; Ahmadi-Simab K; Blank N; Distler JH; Fierlbeck G; Genth E; Guenther C; Hein R; Henes J; Herich L; Herrgott I; Koetter I; Kreuter A; Krieg T; Kuhr K; Lorenz HM; Meier F; Melchers I; Mensing H; Mueller-Ladner U; Pfeiffer C; Riemekasten G; Sárdy M; Schmalzing M; Sunderkoetter C; Susok L; Tarner IH; Vaith P; Worm M; Wozel G; Zeidler G; Hunzelmann N;
Ann Rheum Dis; 2015 Apr; 74(4):730-7. PubMed ID: 24389298
[TBL] [Abstract][Full Text] [Related]
17. Influence of antibody profile in clinical features and prognosis in a cohort of Spanish patients with systemic sclerosis.
Iniesta Arandia N; Simeón-Aznar CP; Guillén Del Castillo A; Colunga Argüelles D; Rubio-Rivas M; Trapiella Martínez L; García Hernández FJ; Sáez Comet L; Egurbide Arberas MV; Ortego-Centeno N; Freire M; Marí Alfonso B; Vargas Hitos JA; Ríos Blanco JJ; Todolí Parra JA; Rodríguez-Carballeira M; Marín Ballvé A; Chamorro Fernández AJ; Pla Salas X; Madroñero Vuelta AB; Ruiz Muñoz M; Fonollosa Pla V; Espinosa G;
Clin Exp Rheumatol; 2017; 35 Suppl 106(4):98-105. PubMed ID: 28980912
[TBL] [Abstract][Full Text] [Related]
18. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.
Nihtyanova SI; Sari A; Harvey JC; Leslie A; Derrett-Smith EC; Fonseca C; Ong VH; Denton CP
Arthritis Rheumatol; 2020 Mar; 72(3):465-476. PubMed ID: 31682743
[TBL] [Abstract][Full Text] [Related]
19. Incidence, prevalence and long-term progression of Goh algorithm rated interstitial lung disease in systemic sclerosis in two independent cohorts in flanders: A retrospective cohort study.
Vandecasteele E; Melsens K; Vanhaecke A; Blockmans D; Bonroy C; Carton C; Deschepper E; De Keyser F; Houssiau F; Piette Y; Vanthuyne M; Verbeke K; Westhovens R; Wuyts WA; De Langhe E; Brusselle G; Smith V
Semin Arthritis Rheum; 2021 Oct; 51(5):969-976. PubMed ID: 34403812
[TBL] [Abstract][Full Text] [Related]
20. Differences Sustained Between Diffuse and Limited Forms of Juvenile Systemic Sclerosis in an Expanded International Cohort.
Foeldvari I; Klotsche J; Kasapcopur O; Adrovic A; Terreri MT; Sakamoto AP; Stanevicha V; Sztajnbok F; Anton J; Feldman B; Alexeeva E; Katsicas M; Smith V; Avcin T; Marrani E; Kostik M; Lehman T; Sifuentes-Giraldo WA; Vasquez-Canizares N; Appenzeller S; Janarthanan M; Moll M; Nemcova D; Patwardhan A; Santos MJ; Sawhney S; Schonenberg-Meinema D; Battagliotti C; Berntson L; Bica B; Brunner J; Costa-Reis P; Eleftheriou D; Harel L; Horneff G; Kaiser D; Kallinich T; Lazarevic D; Minden K; Nielsen S; Nuruzzaman F; Uziel Y; Helmus N; Torok KS
Arthritis Care Res (Hoboken); 2022 Oct; 74(10):1575-1584. PubMed ID: 33787070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
